(NASDAQ: UNCY) Unicycive Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.77%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Unicycive Therapeutics's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast UNCY's revenue for 2025 to be $198,869,431, with the lowest UNCY revenue forecast at $21,954,529, and the highest UNCY revenue forecast at $524,737,368. On average, 3 Wall Street analysts forecast UNCY's revenue for 2026 to be $3,293,058,715, with the lowest UNCY revenue forecast at $475,279,363, and the highest UNCY revenue forecast at $6,003,116,119.
In 2027, UNCY is forecast to generate $8,426,425,662 in revenue, with the lowest revenue forecast at $4,872,940,395 and the highest revenue forecast at $13,732,437,235.